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Motivation: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by the loss of motor neurons. Though 
currently we unknow its etiology, there are several alterations related to its physiopathology, such as mutation in Superoxide 
dismutase-1 (SOD-1), an enzyme which prevents free radical production, and intracellular non-avaliable iron accumulation, 
both alterations have been observed in the patient. The mutated form of this enzyme tends to form fibrillar aggregates on the 
cytoplasm. In this way, the research line have two parts: the molecular characterization of the disease, and the elimination or 
reduction of  intracellular iron accumulation and the reestablishment of modified protein levels. Treatments screening allows to 
increase patient's survival due to we use commercialized compounds, with this approximation we can skip long proccess of 
drugs commercialization. 
Methods: Human Dermal Fibroblast (HDF) primary cultures with and without pathological background are used. Iron 
accumulation in this cultures is observed by Prussian Blue technique. Expression protein levels are measured by Western 
Blotting, TransferBlot, InmmunoBlot and ChemicDoc developing. Quantifications were calculated with ImageJ software. 
Preliminar Results: We observed differences in the expression protein levels involved in autophagy proccess (P62, LC3B), 
antioxidative activity (GPX, SOD1), lipid peroxidation (PLA2G6) and lisosomal dynamic (LAMP1). Drugs screening allowed to 
select several drugs which reduced intracellular iron levels. With this technique we did another screening combining that drugs 
to select the best combination. 
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